Mil60 not checked

Beijing Mabworks Biotech Co., Ltd.

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“15mg/kg in combination with paclitaxel/carboplatin for 6 cycles, then maintains at 7.5mg/kg”In the company’s words, NCT03196986 on ClinicalTrials.gov
Tested for
Non-small Cell Lung Cancer
Main trialPhase 3
“This randomized, double-blind, multi-center phase 3 study is aimed to compare the efficacy and safety of mil60 with bevacizumab as first-line treatment when combined with standard chemotherapy (paclitaxel/carboplatin) in treatment-naive patients with advanced or recurrent non-squamous NSCLC.”In the company’s words, NCT03196986 on ClinicalTrials.gov
Other names
No other intervention name

Other drugs for Non-small Cell Lung Cancer

All 560 drugs for Non-small Cell Lung Cancer

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 3Completed 1 Aug 2019 mil60 Versus Bevacizumab in Patients With Treatment-naïve Non-squamous Non-small Cell Lung Cancer
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Mil60

Following is part of Solo: you see every change to Mil60 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in